Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Amanda Teeple & Timothy Fitzgerald. (2022) Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis. Journal of Dermatological Treatment 33:1, pages 518-524.
Read now
Read now
Amanda Teeple & Erik Muser. (2019) Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis. Journal of Medical Economics 22:12, pages 1268-1273.
Read now
Read now
Anna Campanati, Matteo Paolinelli, Frederico Diotallevi, Emanuela Martina, Elisa Molinelli & Annamaria Offidani. (2019) Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opinion on Drug Metabolism & Toxicology 15:11, pages 913-925.
Read now
Read now
Katherine M. Stiff, Abigail Cline & Steven R. Feldman. (2019) Tracking the price of existing biologics when drugs enter the market. Expert Review of Pharmacoeconomics & Outcomes Research 19:4, pages 375-377.
Read now
Read now
Matteo Megna, Anna Balato, Annunziata Raimondo & Nicola Balato. (2018) Guselkumab for the treatment of psoriasis. Expert Opinion on Biological Therapy 18:4, pages 459-468.
Read now
Read now
Articles from other publishers (12)
Xuan Qi Koh, Hazel H. Oon, Wei‐Sheng Chong, Bernett Lee, Xiahong Zhao & Eugene S. T. Tan. (2023) Clinical and patient‐reported outcomes from the first 4 years of a Psoriasis Biologics Registry in Singapore. Experimental Dermatology 32:11, pages 2023-2028.
Crossref
Crossref
Katrina Cirone & Ronald Vender. (2023) Plaque psoriasis and morphea in a patient on ustekinumab: A case report. SAGE Open Medical Case Reports 11, pages 2050313X2311642.
Crossref
Crossref
Juanjuan Jiao, Xincheng Zhao, Ying Wang, Nannan Liang, Juan Li, Xiaohong Yang, Jianxiao Xing, Ling Zhou, Junqin Li, Ruixia Hou, Xinhua Li & Kaiming Zhang. (2022) Normal mesenchymal stem cells can improve the abnormal function of T cells in psoriasis via upregulating transforming growth factor‐β receptor. The Journal of Dermatology 49:10, pages 988-997.
Crossref
Crossref
U. Mrowietz, R.B. Warren, C.L. Leonardi, D. Saure, H. Petto, S. Hartz, M. Dossenbach & K. Reich. (2021) Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. Journal of the European Academy of Dermatology and Venereology 35:5, pages 1161-1175.
Crossref
Crossref
Juliana Santos Rosa Viegas, Fabíola Garcia Praça, Marcelo Kravicz & Maria Vitoria Lopes Badra Bentley. (2020) Therapeutic applications and delivery systems for triptolide. Drug Delivery and Translational Research 10:6, pages 1584-1600.
Crossref
Crossref
Ranime Jebbawi, Abdelouahd Oukhrib, Emily Clement, Muriel Blanzat, Cédric-Olivier Turrin, Anne-Marie Caminade, Eric Lacoste, Séverine Fruchon & Rémy Poupot. (2020) An Anti-Inflammatory Poly(PhosphorHydrazone) Dendrimer Capped with AzaBisPhosphonate Groups to Treat Psoriasis. Biomolecules 10:6, pages 949.
Crossref
Crossref
Shoufan Wang, Lihong Zhu, Yihou Xu, Zongbi Qin & Aiqin Xu. (2020)
Salvianolic acid B ameliorates psoriatic changes in imiquimod-induced psoriasis on BALB/c mice by inhibiting inflammatory and keratin markers
via
altering phosphatidylinositol-3-kinase/protein kinase B signaling pathway
. The Korean Journal of Physiology & Pharmacology 24:3, pages 213-221.
Crossref
Crossref
A. Svedbom & M. Ståhle. (2019) Real‐world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis. Journal of the European Academy of Dermatology and Venereology 34:3, pages 525-532.
Crossref
Crossref
Kenneth B. Gordon, Chenglong Han, Shu Li, Yin You, Michael Song, Steven Fakharzadeh, Jeffrey J. Crowley & Kristian Reich. (2019) Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies. Journal of Psoriasis and Psoriatic Arthritis 4:3, pages 147-152.
Crossref
Crossref
Alexa B. Steuer, Erik Peterson, Kristen Lo Sicco & Andrew G. FranksJr.Jr.. (2019) Morphea in a patient undergoing treatment with ustekinumab. JAAD Case Reports 5:7, pages 590-592.
Crossref
Crossref
J. A. Mogulevtseva, A. V. Mezentsev & S. A. Bruskin. (2018) Impact of Metalloproteinase 1 Deficiency Induced by Specific Small Hairpin RNA on the Physiological Effects of Tumor Necrosis Factor. Russian Journal of Genetics 54:8, pages 960-966.
Crossref
Crossref
L. Iversen, E. Dauden, S. Segaert, K. Freeman, S. Magina, D. Rigopoulos & D. Thaci. (2017) Reformulations of well‐known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. Journal of the European Academy of Dermatology and Venereology 31:8, pages 1271-1284.
Crossref
Crossref